ICER Misses the Numbers That Matter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
Categorized in: Analysis
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
Categorized in: Analysis